Document is current
Any future updates will be listed below
-
Authors
Zhao, Karena
Vos, Joris https://orcid.org/0000-0002-8318-5455
Lam, Stanley
Boe, Lillian A.
Muldoon, Daniel https://orcid.org/0000-0001-7936-4365
Han, Catherine Y.
Valero, Cristina https://orcid.org/0000-0003-3397-2888
Lee, Mark
Fitzgerald, Conall
Lee, Andrew S. https://orcid.org/0000-0002-2885-6316
Prasad, Manu
Jain, Swati
Deng, Xinzhu
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Bandlamudi, Chaitanya https://orcid.org/0000-0003-1108-4919
Zhou, Xi Kathy
Morris, Luc G. T. https://orcid.org/0000-0002-4417-2280
- License Information
-
More Information
Article History
Received: 21 July 2024
Accepted: 23 April 2025
First Online: 2 June 2025
Competing interests
: M.F.B. reports personal fees from AstraZeneca and Paige.AI; research support from Boundless Bio; and intellectual property rights with SOPHiA Genetics. T.A.C. acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, AN2H and Eisai, has served as an advisor for Bristol Myers Squibb, Illumina, Eisai and AN2H, holds equity in AN2H and is a cofounder of Gritstone Oncology and holds equity in the company. T.A.C. and L.G.T.M. are listed inventors on intellectual property held by Memorial Sloan Kettering Cancer Center, unrelated to this work. The other authors declare no competing interests.
